SBC (Sanhuang Xiexin Tang combined with Baihu Tang plus Cangzhu) alleviates NAFLD by enhancing mitochondrial biogenesis and ameliorating inflammation in obese patients and mice.

Zhitao REN; Gemin XIAO; Yixin CHEN; Linli WANG; Xiaoxin XIANG; Yi YANG; Siying WEN; Zhiyong XIE; Wenhui LUO; Guowei LI; Wenhua ZHENG; Xiaoxian QIAN; Rihan HAI; Liansheng YANG; Yanhua ZHU; Mengyin CAI; Yinong YE; Guojun SHI; Yanming CHEN

Return

SBC (Sanhuang Xiexin Tang combined with Baihu Tang plus Cangzhu) alleviates NAFLD by enhancing mitochondrial biogenesis and ameliorating inflammation in obese patients and mice.

Author: Zhitao REN ¹ ; Gemin XIAO ² ; Yixin CHEN ¹ ; Linli WANG ³ ; Xiaoxin XIANG ¹ ; Yi YANG ¹ ; Siying WEN ¹ ; Zhiyong XIE ⁴ ; Wenhui LUO ⁵ ; Guowei LI ⁵ ; Wenhua ZHENG ⁶ ; Xiaoxian QIAN ³ ; Rihan HAI ⁷ ; Liansheng YANG ⁷ ; Yanhua ZHU ¹ ; Mengyin CAI ¹ ; Yinong YE ^{8
,

9} ; Guojun SHI ¹⁰ ; Yanming CHEN ¹¹
Author Information

1. Department of Endocrinology & Metabolism, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China; Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China; Guangzhou Municipal Key Laboratory of Mechanistic and Translational Obesity Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China; Medical Center for Comprehensive Weight Control, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China.
2. Medical Center for Comprehensive Weight Control, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China; Department of Traditional Chinese Medicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510000, China.
3. Department of Cardiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510000, China.
4. School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 518000, China.
5. Guangdong e-fong Pharmaceutical Co., Ltd., Foshan 528000, China.
6. Faculty of Health Sciences, University of Macau, Macau 999078, China.
7. Department of Traditional Chinese Medicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510000, China.
8. Foshan Fourth People's Hospital, Foshan 528000, China. Electronic address: fsyyn001@
9. com.
10. Department of Endocrinology & Metabolism, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China; Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China; Guangzhou Municipal Key Laboratory of Mechanistic and Translational Obesity Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China; Medical Center for Comprehensive Weight Control, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China. Electronic address: shigj6@mail.sysu.edu.cn.
11. Department of Endocrinology & Metabolism, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China; Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China; Guangzhou Municipal Key Laboratory of Mechanistic and Translational Obesity Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China; Medical Center for Comprehensive Weight Control, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China. Electronic address: chyanm@mail.sysu.edu.cn.
Publication Type:Journal Article
Keywords: Clinical observation; Lipid metabolism; Mitochondrial biogenesis; Non-alcoholic fatty liver disease; Obesity; Traditional Chinese medicine
MeSH: Humans; Mice; Animals; Non-alcoholic Fatty Liver Disease/metabolism*; NF-kappa B/metabolism*; Organelle Biogenesis; Retrospective Studies; Mice, Inbred C57BL; Obesity/metabolism*; Liver; Inflammation/metabolism*; Body Weight; Lipid Metabolism; Lipids; Diet, High-Fat/adverse effects*
From: Chinese Journal of Natural Medicines (English Ed.) 2023;21(11):830-841
CountryChina
Language:English
Abstract: In the context of non-alcoholic fatty liver disease (NAFLD), characterized by dysregulated lipid metabolism in hepatocytes, the quest for safe and effective therapeutics targeting lipid metabolism has gained paramount importance. Sanhuang Xiexin Tang (SXT) and Baihu Tang (BHT) have emerged as prominent candidates for treating metabolic disorders. SXT combined with BHT plus Cangzhu (SBC) has been used clinically for Weihuochisheng obese patients. This retrospective analysis focused on assessing the anti-obesity effects of SBC in Weihuochisheng obese patients. We observed significant reductions in body weight and hepatic lipid content among obese patients following SBC treatment. To gain further insights, we investigated the effects and underlying mechanisms of SBC in HFD-fed mice. The results demonstrated that SBC treatment mitigated body weight gain and hepatic lipid accumulation in HFD-fed mice. Pharmacological network analysis suggested that SBC may affect lipid metabolism, mitochondria, inflammation, and apoptosis-a hypothesis supported by the hepatic transcriptomic analysis in HFD-fed mice treated with SBC. Notably, SBC treatment was associated with enhanced hepatic mitochondrial biogenesis and the inhibition of the c-Jun N-terminal kinase (JNK)/nuclear factor-kappa B (NF-κB) and extracellular signal-regulated kinase (ERK)/NF-κB pathways. In conclusion, SBC treatment alleviates NAFLD in both obese patients and mouse models by improving lipid metabolism, potentially through enhancing mitochondrial biogenesis. These effects, in turn, ameliorate inflammation in hepatocytes.